TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence
Completed
- Conditions
- Stress Urinary Incontinence
- Registration Number
- NCT00463554
- Lead Sponsor
- Ethicon, Inc.
- Brief Summary
The primary objective of this study is to obtain clinical performance information on the GYNECARE TVT-SECUR\* System (Tension-free Support for Incontinence) in women with stress urinary incontinence (SUI).
- Detailed Description
The primary variable for effectiveness is \> 50% improvement on the subjective symptom Visual Analog Scale (VAS) at Visit 3/Week 5 (35 days post-surgery) to be accepted.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 72
Inclusion Criteria
- Must be female with objective, demonstratable signs of SUI or stress predominant mixed incontinence and requires elective, primary surgical intervention.
- Must be at least 21 years old.
- Must be postmenopausal (amenorrhea) for at least 1 year or surgically sterile (bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy) or has a negative pregnancy test prior to study entry and has decided to cease childbearing.
- Agrees to participate in the study, including all study related procedures and evaluations and documents this agreement by signing the IRB/EC-approved informed consent
Exclusion Criteria
- Have any other coexistent pathology requiring concomitant surgery that may impact this procedure i.e. surgeries that involve the anterior vaginal wall (e.g. anterior colporrhaphy, diverticula, anterior Prolift) Any allowable concomitant surgery must be performed prior to the GYNECARE TVT SECUR System surgery.
- Have intrinsic sphincter deficiency (ISD) [Urethral Pressure Profile (UPP) with a maximum urethral closing pressure (MUCP) < 20cm H2O or Leak Point Pressure (LPP) < 60].
- Have an active urinary tract infection (UTI) or vaginal infection at time of surgery.
- Have a fixed urethra (< 30° mobility on Q-Tip Straining Test).
- Have had prior incontinence surgery.
- Have a post-void residual volume > 100mL.
- Have co-existent pelvic organ prolapse that is symptomatic or extends beyond the hymen.
- Have lower urinary tract pathology in the form of a fistula or diverticulum.
- Have a malignancy or with a history of malignancy within the past 5 years, except for a basal cell carcinoma that has been treated with local excision and is no longer present.
- Are on anticoagulant therapy.
- Have received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment.
- Are deemed by the investigator as medically unfit for surgery or who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the GYNECARE TVT SECUR System IFU.
- Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical performance of TVT-SECUR* Screening and Day 35
- Secondary Outcome Measures
Name Time Method Intra- and post-operative complications Intraoperative, Week 5, Months 6 and 12 Anesthesia intraoperative Operative time Intraoperative Assessment of the results of the standing cough stress test Screening, Week 5, Months 6 and 12 Physician questionnaire results Months 2 and 12 Urodynamics Screening, Week 5, Months 6 and 12 (post-operative optional) QoL measures Screening, Week 5, Months 6 and 12 Subject satisfaction. Month 12
Trial Locations
- Locations (6)
Michigan Institute of Women's Health
🇺🇸Dearborn, Michigan, United States
Good Samaritan Hospital
🇺🇸Cincinnati, Ohio, United States
The Institute for Female Pelvic Medicine and Reconstructive Surgery
🇺🇸Allentown, Pennsylvania, United States
Vanderbilt University
🇺🇸Nashville, Tennessee, United States
University of Padova
🇮🇹Padova, Italy
Helsinki University Central Hospital
🇫🇮Helsinki, Finland